CitraNOX 120 CT

CitraNOX 120 CT by Ortho Molecular Products

CitraNOX by Ortho Molecular Products is a dietary supplement designed to support cardiovascular health by maintaining normal inflammatory balance, nitric oxide (NO) levels, smooth muscle integrity, and optimizing vasodilation of key coronary arteries.* It may also reduce the impact of stress on your vascular arteries caused by aging.*

Who Is CitraNOX 120 CT for?

CitraNOX 120 CT by Ortho Molecular Products may support your health if you:

• struggle from vascular conditions related to aging*
• seek to improve overall heart health*

CitraNOX 120 CT by Ortho Molecular Products—Effects?

CitraNOX 120 CT may have the following effects:

• supporting normal inflammatory balance and nitric oxide levels*
• maintaining smooth muscle integrity and optimizing vasodilation*
• mitigating the impact of stress on coronary arteries caused by aging*

Supplements support your health but do not replace a balanced diet. Always check with your healthcare practitioner if you have doubts about a new supplement. Book a FREE product consultation to learn more about CitraNOX 120 CT.

Recommendation:
Ortho Molecular Products suggests taking 4 CitraNOX capsules per day or as recommended by your health care professional.

Serving Size: 4 Capsules
Servings Per Container: 30

Amount Per Serving:
L-Citrulline 3 g
Grape Seed Extract (MegaNatural®-BP) 200 mg
Quercetin Dihydrate 200 mg

Other Ingredients: Natural Vegetable Capsules, Stearic Acid, and Magnesium Stearate.

Does Not Contain: Gluten, corn, yeast, artificial colors and flavors.

Cautions: If you are pregnant or nursing, consult your health care professional before taking CitraNOX by Ortho Molecular Products.

Click here to view Product Info Sheet

References:

1. Black, P. H., & Garbutt, L. D. (2002). Stress, inflammation, and cardiovascular disease. Journal of Psychosomatic Research, 52, 1–23.
2. Tracy, R. (2003). Emerging relationships of inflammation, cardiovascular disease, and chronic diseases of aging. International Journal of Obesity & Related Metabolic Disorders, 27.
3. Palmer, R. M., Ferrige, A., & Moncada, S. (1987). Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.
4. Furchgott, R., & Jothianandan, D. (1991). Endothelium-dependent and -independent vasodilation involving cyclic GMP: Relaxation induced by nitric oxide, carbon monoxide, and light. Journal of Vascular Research, 28, 52–61.
5. Vallance, P., Collier, J., & Moncada, S. (1989). Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. The Lancet, 334, 997–1000.
6. Pérez-Guisado, J., & Jakeman, P. M. (2010). Citrulline malate enhances athletic anaerobic performance and relieves muscle soreness. The Journal of Strength & Conditioning Research, 24, 1215–1222.
7. Bailey, S. J., Blackwell, J. R., Lord, T., Vanhatalo, A., Winyard, P. G., & Jones, A. M. (2015). L-citrulline supplementation improves O2 uptake kinetics and high-intensity exercise performance in humans. Journal of Applied Physiology, 119, 385–395.
8. Suzuki, T., Morita, M., Kobayashi, Y., & Kamimura, A. (2015). Oral L-citrulline supplementation enhances cycling time trial performance in healthy well-trained males. Journal of the International Society of Sports Nutrition, 12(P52).
9. Nagaya, N., Uematsu, M., Oya, H., Sato, N., Sakamaki, F., Kyotani, S., Ueno, K., Nakanishi, N., Yamagishi, M., & Miyatake, K. (2001). Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine, 163, 887–891.
10. Wagenmakers, A. J. (1999). Amino acid supplements to improve athletic performance. Current Opinion in Clinical Nutrition & Metabolic Care, 2, 539–544.
11. Cannon, R. O. (1998). Role of nitric oxide in cardiovascular disease: Focus on the endothelium. Clinical Chemistry, 44, 1809–1819.
12. Radomski, M. W., Palmer, R. M., & Moncada, S. (1987). The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochemical and Biophysical Research Communications, 148, 1482–1489.
13. Napoli, C., & Ignarro, L. J. (2001). Nitric oxide and atherosclerosis. Nitric Oxide, 5, 88–97.
14. Romero, M. J., Platt, D. H., Caldwell, R. B., & Caldwell, R. W. (2006). Therapeutic use of citrulline in cardiovascular disease. Cardiovascular Drug Reviews, 24, 275–290.
15. Durante, W., Johnson, F. K., & Johnson, R. A. (2007). Arginase: A critical regulator of nitric oxide synthesis and vascular function. Clinical and Experimental Pharmacology and Physiology, 34, 906–911.
16. Pollock, J. S., Förstermann, U., Mitchell, J. A., Warner, T. D., Schmidt, H., Nakane, M., & Murad, F. (1991). Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proceedings of the National Academy of Sciences, 88, 10480–10484.
17. Morris, S. M. (2006). Arginine: Beyond protein. The American Journal of Clinical Nutrition, 83, 508S–512S.
18. Ryall, J. C., Quantz, M. A., & Shore, G. C. (1986). Rat liver and intestinal mucosa differ in the developmental pattern and hormonal regulation of carbamoyl-phosphate synthetase I and ornithine carbamoyl transferase gene expression. European Journal of Biochemistry, 156, 453–458.
19. Schwedhelm, E., Maas, R., Freese, R., Jung, D., Lukacs, Z., Jambrecina, A., Spickler, W., Schulze, F., & Böger, R. H. (2008). Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: Impact on nitric oxide metabolism. British Journal of Clinical Pharmacology, 65, 51–59.
20. Morita, M., Hayashi, T., Ochiai, M., Maeda, M., Yamaguchi, T., Ina, K., & Kuzuya, M. (2014). Oral supplementation with a combination of L-citrulline and L-arginine rapidly increases plasma L-arginine concentration and enhances NO bioavailability. Biochemical and Biophysical Research Communications, 454, 53–57.
21. Bito, T., Roy, S., Sen, C. K., Shirakawa, T., Gotoh, A., Ueda, M., Ichihashi, M., & Packer, L. (2002). Flavonoids differentially regulate IFNγ-induced ICAM-1 expression in human keratinocytes: Molecular mechanisms of action. FEBS Letters, 520, 145–152.
22. Min, Y. D., Choi, C. H., Bark, H., Son, H. Y., Park, H. H., Lee, S., Park, J. W., Park, E. K., Shin, H. I., & Kim, S. H. (2007). Quercetin inhibits expression of inflammatory cytokines through attenuation of NF-κB and p38 MAPK in HMC-1 human mast cell line. Inflammation Research, 56, 210–215.
23. Sanchez, M., Galisteo, M., Vera, R., Villar, I. C., Zarzuelo, A., Tamargo, J., Pérez-Vizcaíno, F., & Duarte, J. (2006). Quercetin downregulates NADPH oxidase, increases eNOS activity, and prevents endothelial dysfunction in spontaneously hypertensive rats. Journal of Hypertension, 24, 75–84.
24. Plotnick, G. D., Corretti, M. C., Vogel, R. A., Hesslink, R., & Wise, J. A. (2003). Effect of supplemental phytonutrients on impairment of the flow-mediated brachial artery vasoactivity after a single high-fat meal. Journal of the American College of Cardiology, 41, 1744–1749.
25. Edirisinghe, I., Burton-Freeman, B., & Kappagoda, C. T. (2008). Mechanism of the endothelium-dependent relaxation evoked by a grape seed extract. Clinical Science, 114, 331–337.
26. Sivaprakasapillai, B., Edirisinghe, I., Randolph, J., Steinberg, F., & Kappagoda, T. (2009). Effect of grape seed extract on blood pressure in subjects with the metabolic syndrome. Metabolism, 58, 1743–1746.